Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Hancock Jaffe Laboratories Inc (HJLI)

Hancock Jaffe Laboratories Inc (HJLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,146
  • Shares Outstanding, K 8,685
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,140 K
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.21
Trade HJLI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.26
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/16/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +66,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.60 +36.58%
on 09/07/21
11.38 -8.79%
on 09/29/21
+2.69 (+34.98%)
since 08/30/21
3-Month
5.36 +93.66%
on 07/19/21
11.38 -8.79%
on 09/29/21
+3.51 (+51.09%)
since 06/30/21
52-Week
4.99 +108.02%
on 05/13/21
17.68 -41.29%
on 12/11/20
-0.44 (-4.11%)
since 09/30/20

Most Recent Stories

More News
enVVeno Medical Corporation Successfully Completes Rebranding

Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

HJLI : 10.38 (-1.98%)
enVVeno Medical Corporation Successfully Completes Rebranding

Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

HJLI : 10.38 (-1.98%)
Chart of the Day: IHeart Hancock Jaffe

The Barchart Chart of the Day belongs to the healthcare company Hancock Jaffe Laboratories (NASDAQ: HJLI ). I found the stock by sorting Barchart's Top Stocks to Own list first by the most frequent...

HJLI : 10.38 (-1.98%)
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe...

HJLI : 10.38 (-1.98%)
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve®...

HJLI : 10.38 (-1.98%)
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe"...

HJLI : 10.38 (-1.98%)
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered...

HJLI : 10.38 (-1.98%)
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had...

HJLI : 10.38 (-1.98%)
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVVE...

HJLI : 10.38 (-1.98%)
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices...

HJLI : 10.38 (-1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg...

See More

Key Turning Points

3rd Resistance Point 11.16
2nd Resistance Point 10.95
1st Resistance Point 10.67
Last Price 10.38
1st Support Level 10.18
2nd Support Level 9.97
3rd Support Level 9.69

See More

52-Week High 17.68
Fibonacci 61.8% 12.83
Fibonacci 50% 11.34
Last Price 10.38
Fibonacci 38.2% 9.84
52-Week Low 4.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar